Derks Marloes G M, de Glas Nienke A, Bastiaannet Esther, de Craen Anton J M, Portielje Johanneke E A, van de Velde Cornelis J H, van Leeuwen Floor E, Liefers Gerrit-Jan
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
Oncologist. 2016 Aug;21(8):946-53. doi: 10.1634/theoncologist.2016-0033. Epub 2016 Jul 1.
BACKGROUND: Previous retrospective studies have shown that physical functioning in older cancer survivors is affected after treatment, yet prospective data are lacking. The aim of this study was to assess change in physical functioning in different age groups of patients with hormone receptor-positive breast cancer who were enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase III trial. METHODS: Two physical parameters were assessed. Physical functioning was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire 1 year (T1) and 2 years (T2) after diagnosis. Physical activity was measured in metabolic equivalent of task (MET) hours/week at T1 and T2. Physical activity before diagnosis (T0) was assessed retrospectively at the T1 questionnaire. Patients were divided into three age groups: <60, 60-69, and ≥70 years. Decline in physical functioning was assessed using linear regression analysis. Differences in mean values of physical activity levels were calculated using repeated-measures one-way analysis of variance. RESULTS: A total of 431 patients were included for analysis. In all age groups, physical activity levels at T1 and T2 were significantly lower than prediagnostic physical activity levels (T0) (p < .001 for all age groups). Age ≥70 years was independently associated with decline in physical functioning between T1 and T2 (β = -4.62, 95% confidence interval -8.73 to -0.51, p = .028). CONCLUSION: Patients aged 70 years or older treated with breast surgery and adjuvant hormonal therapy did not improve between years 1 and 2 after diagnosis to the same extent as did younger patients. IMPLICATIONS FOR PRACTICE: Although older patients constitute a large share of the breast cancer population, little is known about the effect and consequences of treatment of breast cancer in this specific age group. This study revealed that, unlike younger patients, older patients do not regain their physical abilities after surgical and adjuvant treatment for breast cancer. In older adults, the effect of treatment on physical functioning and independency could be more relevant than survival outcomes. Clinicians and older patients should be aware of the impact of treatment on physical functioning and prevent older patients from experiencing physical decline, which could lead to institutionalization and loss of independence. There is a need for age-specific guidelines that take into account the heterogeneity of the older population and for evidence-based treatment that focuses not only on cancer-specific outcomes but also on the consequences of treatment for physical and cognitive functioning and quality of life.
背景:既往回顾性研究表明,老年癌症幸存者的身体功能在治疗后会受到影响,但前瞻性数据尚缺。本研究旨在评估参加他莫昔芬依西美坦辅助治疗多国(TEAM)Ⅲ期试验的激素受体阳性乳腺癌患者不同年龄组的身体功能变化。 方法:评估两项身体参数。使用欧洲癌症研究与治疗组织(EORTC)QLQ-C30问卷在诊断后1年(T1)和2年(T2)评估身体功能。在T1和T2时以代谢当量任务(MET)小时/周来测量身体活动量。在T1问卷中对诊断前(T0)的身体活动进行回顾性评估。患者被分为三个年龄组:<60岁、60 - 69岁和≥70岁。使用线性回归分析评估身体功能的下降情况。使用重复测量单因素方差分析计算身体活动水平均值的差异。 结果:共纳入431例患者进行分析。在所有年龄组中,T1和T2时的身体活动水平均显著低于诊断前的身体活动水平(T0)(所有年龄组p <.001)。年龄≥70岁与T1和T2之间身体功能的下降独立相关(β = -4.62,95%置信区间 -8.73至 -0.51,p =.028)。 结论:接受乳房手术和辅助激素治疗的70岁及以上患者在诊断后1至2年未像年轻患者那样有同等程度的改善。 对实践的启示:尽管老年患者在乳腺癌人群中占很大比例,但对于这一特定年龄组乳腺癌治疗的效果和后果知之甚少。本研究表明,与年轻患者不同,老年患者在接受乳腺癌手术和辅助治疗后无法恢复其身体能力。在老年人中,治疗对身体功能和独立性的影响可能比生存结果更重要。临床医生和老年患者应意识到治疗对身体功能的影响,并防止老年患者身体功能下降,这可能导致入住养老院和失去独立性。需要有考虑老年人群异质性的针对特定年龄的指南,以及不仅关注癌症特异性结果,还关注治疗对身体和认知功能及生活质量影响的循证治疗。
Dan Med Bull. 2010-9
Breast J. 2024-7-15
J Natl Cancer Inst. 2024-12-1
Clin Geriatr Med. 2016-2
Front Public Health. 2014-9-19
J Natl Cancer Inst. 2014-3-19
CA Cancer J Clin. 2013-10-1
Cancer Treat Rev. 2013-4-19